Specno has launched its AI-powered Research and Development acceleration suite, which will help companies to fast-track R&D to speed up and reduce the cost of product development across sectors.
“The world is already witnessing the impact of AI-driven R&D in specific sectors,” says Daniel Novitzkas, chairman of Specno.
“The prime example is Nvidia’s BioNeMo, a set of tools that accelerate drug research and development using AI. BioNemo’s tools use AI to design, predict, and optimize biomolecules, making drug discovery cheaper and faster than ever.
“In the same way Nvidia’s BioNeMo has transformed drug discovery using AI, Specno is bringing that kind of speed, intelligence, and efficiency to all industries. From fintech and retail to agriculture and e-commerce, our platform is built to supercharge product development at scale.”
Unlike traditional R&D, which is expensive and time-consuming, Specno’s suite leverages advanced AI models to predict, simulate, and optimize product development. This enables deeper insights, faster iterations, and superior products.
Currently, Specno supports more than 200 clients worldwide across 28 industries, including major corporations in food and clothing retail, financial services, and blockchain platforms. Locally, Specno’s clients include brands like PEP, Old Mutual, Ackermans and Quicket.
“Specno already plays a critical role in creating tailored digital solutions for our clients to ensure that they are at the forefront of innovation and productivity,” Novitzkas adds. “This new suite is an extension of this mission, in recognition of the growing and seismic impact of AI on every sector of the global economy throughout this decade.”